China’s regulator cleared the first brain‑computer interface (BCI) for commercial use while a Shanghai cell‑therapy developer secured US trial authorization, marking consecutive regulatory wins for Chinese companies. Shanghai‑based Neuracle Medical Technology received approval to sell a coin‑sized wireless cortical implant for people with spinal cord injuries, the first such commercial BCI cleared in the world. The device records cortical activity and decodes signals to enable cursor or prosthetic control. Separately, Shanghai Unixell secured FDA clearance to begin clinical testing of its cell‑therapy candidate, according to company statements. The US trial nod signals growing international acceptance of Chinese cell and gene therapy developers and could accelerate cross‑border clinical programs. Cell and gene therapies involve living cells or genetic material to treat disease; regulatory acceptance in major markets is a gating factor for commercialization. Taken together, the two developments highlight China’s accelerating footprint in advanced neurotechnology and cellular medicine and set a precedent for other Chinese firms seeking earlier global trial access. Companies named in coverage include Neuracle and Unixell; competing and comparative efforts in the U.S. include Neuralink, Synchron and Paradromics, which remain in clinical testing or trials.